Skip to main content
. Author manuscript; available in PMC: 2016 Aug 25.
Published in final edited form as: Lung Cancer. 2015 Apr 22;89(1):76–79. doi: 10.1016/j.lungcan.2015.04.004

Table 1.

Copy number alterations in addition to the KIF5B-RET fusion. Interestingly AKT2 amplification seen is a critical component of the PI3K/mTOR pathway, alterations of which has been associated with both de novo and acquired resistance to targeted therapy. The addition of the rapamycin analog everolimus may have both overcome the AKT amplification to produce a response in addition to its direct effects on the RET gene. In addition there was full homozygous loss of CDKN2A/B.

Gene Copy Number Position
MDM2 9 chr12:69153996-69277205
NFKBIA 10 chr14:35871177-35873850
NKX2-1 10 chr14:36947748-37023501
CCNE1 8 chr19:30253918-30360638
AKT2 8 chr19:40701261-40791492
AXL 8 chr19:41725275-41765809
CDKN2A 0 chr9:21853212-21998002
CDKN2B 0 chr9:21998748-22101832